OncoMatch/Clinical Trials/NCT05211570
AB8939 in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Is NCT05211570 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies multiple treatments including AB8939 and Venetoclax for acute myeloid leukemia refractory.
Treatment: AB8939 · Venetoclax — The primary objective is to define the safety and tolerability of AB8939 in patients with AML by determining the dose-limiting toxicities, the maximum tolerated dose, and the recommended dose for dose expansion study.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Other
Cancer type
Acute Myeloid Leukemia
Myelodysplastic Syndrome
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: hematopoietic stem cell transplantation
Exception: HSCT within 100 days prior to the first administration of AB8939
Patients with HSCT within 100 days prior to the first administration of AB8939
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- MD Anderson Cancer Center · Houston, Texas
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT05211570 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior hematopoietic stem cell transplantation disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify